Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.

BACKGROUND No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown. METHODS We conducted this phase 3, multicenter, double-blind, randomized, placebo-controlled trial involving children 1 to 3 years of age with peanut allergy confirmed by a double-blind, placebo-controlled food challenge. Patients who had an eliciting dose (the dose necessary to elicit an allergic reaction) of 300 mg or less of peanut protein were assigned in a 2:1 ratio to receive epicutaneous immunotherapy delivered by means of a peanut patch (intervention group) or to receive placebo administered daily for 12 months. The primary end point was a treatment response as measured by the eliciting dose of peanut protein at 12 months. Safety was assessed according to the occurrence of adverse events during the use of the peanut patch or placebo. RESULTS Of the 362 patients who underwent randomization, 84.8% completed the trial. The primary efficacy end point result was observed in 67.0% of children in the intervention group as compared with 33.5% of those in the placebo group (risk difference, 33.4 percentage points; 95% confidence interval, 22.4 to 44.5; P<0.001). Adverse events that occurred during the use of the intervention or placebo, irrespective of relatedness, were observed in 100% of the patients in the intervention group and 99.2% in the placebo group. Serious adverse events occurred in 8.6% of the patients in the intervention group and 2.5% of those in the placebo group; anaphylaxis occurred in 7.8% and 3.4%, respectively. Serious treatment-related adverse events occurred in 0.4% of patients in the intervention group and none in the placebo group. Treatment-related anaphylaxis occurred in 1.6% in the intervention group and none in the placebo group. CONCLUSIONS In this trial involving children 1 to 3 years of age with peanut allergy, epicutaneous immunotherapy for 12 months was superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms. (Funded by DBV Technologies; EPITOPE ClinicalTrials.gov number, NCT03211247.).

[1]  M. Greenhawt,et al.  The Impact of Allergy Specialty Care on Healthcare Utilization Among Peanut Allergy Children in the United States. , 2022, The journal of allergy and clinical immunology. In practice.

[2]  A. Lowe,et al.  The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. , 2022, The Journal of allergy and clinical immunology.

[3]  J. Baumert,et al.  Peanut Cross-contamination in Randomly Selected Baked Goods. , 2022, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  Joanne P Yeung,et al.  Real-world peanut OIT in infants may be safer than non-infant preschool OIT, and equally effective. , 2021, The journal of allergy and clinical immunology. In practice.

[5]  William H. Yang,et al.  Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. , 2021, The journal of allergy and clinical immunology. In practice.

[6]  A. Muraro,et al.  Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry , 2020, Allergy.

[7]  William H. Yang,et al.  Long-Term, Open-Label Extension Study of the Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Children: PEOPLE 3-Year Results. , 2020, The Journal of allergy and clinical immunology.

[8]  C. Dant,et al.  Food Allergy from Infancy Through Adulthood. , 2020, The journal of allergy and clinical immunology. In practice.

[9]  Todor A Popov,et al.  Prevalence of Food Sensitization and Food Allergy in Children across Europe. , 2020, The journal of allergy and clinical immunology. In practice.

[10]  B. Remington,et al.  Risk Reduction in Peanut Immunotherapy. , 2020, Immunology and allergy clinics of North America.

[11]  Douglas H. Jones,et al.  Review Article: Unmet needs of children with peanut allergy: aligning the risks and the evidence. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  M. Greenhawt,et al.  Commercial Claims Costs Related to Healthcare Resource Use Associated With a Diagnosis of Peanut Allergy. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[13]  William H. Yang,et al.  Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial , 2019, JAMA.

[14]  K. Nadeau,et al.  Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in Young Children: 749 , 2019, Journal of Allergy and Clinical Immunology.

[15]  K. Nadeau,et al.  The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States , 2018, Pediatrics.

[16]  J. Trainor,et al.  Food-induced anaphylaxis in infants and children. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[17]  D. Matlock,et al.  Understanding caregiver goals, benefits, and acceptable risks of peanut allergy therapies. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  N. Shah,et al.  National trends in emergency department visits and hospitalizations for food‐induced anaphylaxis in US children , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[19]  T. Dwyer,et al.  Food allergy and gastrointestinal disease The prevalence of food allergy and other allergic diseases in early childhood in a population-based study : HealthNuts age 4-year follow-up , 2022 .

[20]  A. DunnGalvin,et al.  Quality of life in childhood, adolescence and adult food allergy: Patient and parent perspectives , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[21]  B. Vickery,et al.  Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy , 2017, The Journal of allergy and clinical immunology.

[22]  James T.C. Li,et al.  Prospective Validation of the NIAID/FAAN Criteria for Emergency Department Diagnosis of Anaphylaxis. , 2016, The journal of allergy and clinical immunology. In practice.

[23]  O. Bruyère,et al.  Peanut‐allergic patients in the MIRABEL survey: characteristics, allergists’ dietary advice and lessons from real life , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  M. Ben-Shoshan,et al.  Accidental exposures to peanut in a large cohort of Canadian children with peanut allergy , 2015, Clinical and Translational Allergy.

[25]  A. Sheikh,et al.  Prevalence of common food allergies in Europe: a systematic review and meta‐analysis , 2014, Allergy.

[26]  Kirsten Beyer,et al.  Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. , 2012, The Journal of allergy and clinical immunology.

[27]  Anne Muñoz-Furlong,et al.  Further fatalities caused by anaphylactic reactions to food, 2001-2006. , 2007, The Journal of allergy and clinical immunology.

[28]  C. Akdis,et al.  Treatment for food allergy , 2018, The Journal of allergy and clinical immunology.

[29]  J. Fine,et al.  Early oral immunotherapy in peanut‐allergic preschool children is safe and highly effective , 2017, The Journal of allergy and clinical immunology.

[30]  M. Goldberg,et al.  Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. , 2014, The journal of allergy and clinical immunology. In practice.